212 related articles for article (PubMed ID: 32763241)
1. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.
Noureddin M; Jones C; Alkhouri N; Gomez EV; Dieterich DT; Rinella ME;
Gastroenterology; 2020 Nov; 159(5):1985-1987.e4. PubMed ID: 32763241
[No Abstract] [Full Text] [Related]
2. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
3. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
5. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
6. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
Tilg H
Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
[No Abstract] [Full Text] [Related]
7. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.
Phisalprapa P; Supakankunti S; Charatcharoenwitthaya P; Apisarnthanarak P; Charoensak A; Washirasaksiri C; Srivanichakorn W; Chaiyakunapruk N
Medicine (Baltimore); 2017 Apr; 96(17):e6585. PubMed ID: 28445256
[TBL] [Abstract][Full Text] [Related]
10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
11. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.
Corey KE; Klebanoff MJ; Tramontano AC; Chung RT; Hur C
Dig Dis Sci; 2016 Jul; 61(7):2108-17. PubMed ID: 26825843
[TBL] [Abstract][Full Text] [Related]
12. Testing and Treating Helicobacter pylori Infection in Individuals With Family History of Gastric Cancer is Cost-effective.
Rustgi SD; Oh A; Hur C
Gastroenterology; 2021 Dec; 161(6):2051-2052.e4. PubMed ID: 34461053
[No Abstract] [Full Text] [Related]
13. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
14. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
15. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.
Ciardullo S; Sala I; Perseghin G
Diabetes Res Clin Pract; 2020 Sep; 167():108358. PubMed ID: 32745698
[TBL] [Abstract][Full Text] [Related]
16. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
Chongmelaxme B; Phisalprapa P; Sawangjit R; Dilokthornsakul P; Chaiyakunapruk N
Pharmacoeconomics; 2019 Feb; 37(2):267-278. PubMed ID: 30430467
[TBL] [Abstract][Full Text] [Related]
17. Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis.
Iragorri N; Hazlewood G; Manns B; Bojke L; Spackman E;
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):266-274. PubMed ID: 31733035
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Klebanoff MJ; Corey KE; Samur S; Choi JG; Kaplan LM; Chhatwal J; Hur C
JAMA Netw Open; 2019 Feb; 2(2):e190047. PubMed ID: 30794300
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
